Saturday, 20 Apr 2019
ARTICLE SEARCH
YearIss.
Keyword
Author
VJPM
Page: 57
Volume XXV, Issue 2(162) 2015
Efficacy of one year entecavir/tenofovir disoproxil fumarate therapy in HbeAg-negative chronic Hepatitis B patients
Author: Nguyen Van Dung, Nguyen Thuy Linh, Do Huy Duong, Nguyen Tuan Nghia, Trinh Thi Ngoc and Nguyen Thi Lan Anh
Summary:
Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent nucleotide analogs used against the hepatitis B virus (HBV). The efficacy of one-year treatment with ETV and TDF in HBeAg-negative chronic hepatitis B (CHB) patients who had not received a nucleoside analog previously was assessed in the present study. A total of 86 eligible HBeAg-negative CHB patients were recruited and randomly assigned to ETV and TDF therapies. Patients in the ETV group (N = 42) were administered 0.5 mg of ETV (Baraclude by Bristol Meyer Squibb) daily at 2 h after meals, whereas the TDF group (N = 44) received 300 mg of TDF (Virkil by Strides Arcolab or Protevir by Incepta Pharmaceuticals, Ltd.) daily. Efficacy analysis was conducted among patients who completed one year of treatment with good adherence and full follow-ups (ETV: n = 31 and TDF: n = 28). Results showed that ETV (Baraclude) was associated with high biochemical responses and virological responses (VRs), with 66.7% presenting amino-transferase normalization. HBV DNA was not detected in 80% of the patients who received ETV after one year of therapy. In comparison, TDF therapy obtained a lower rate of biochemical response (53.9%) and viral suppression (57.7%). Drug resistance testing for all cases with viral breakthroughs found no resistance mutations. Multivariate analysis showed that low HBV viral load at the baseline was associated with VR after one year of therapy. In total, ETV (Baraclude) is an effective drug for CHB therapy, and the efficacy of TDF (Virkil by Strides Arcolab or Protevir by Incepta Pharmaceuticals, Ltd.) needs to be followed-up in longer-term therapy and needs to be compared with other TDF brand names available in Vietnam
Keywords:
Chronic Hepatitis B (CHB), Entecavir (ETV), Hepatitis B virus (HBV), Hepatitis B e-antigen (HBeAg), Tenofovir disoproxil (TDF), viral suppression, biochemical response
File:
vjpm_org57_1_2015.pdf
Download:
Download with member account.
 
Others:
Happy New Year 2019! Year of the Pig
The Vietnam Journal of Preventive Medicine wish all readers with healthy, happiness and prosperity in the year of the Pig. Happy New Year 2019
Thiết kế web: OnIP™